(Q43033327)

12 November 2017

title

Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. (English)

1 reference

12 November 2017

0 references

1

Kazuaki Chayama

1 reference

12 November 2017

2

C Nelson Hayes

1 reference

12 November 2017

17

Hiromitsu Kumada

1 reference

12 November 2017

10

Namiki Izumi

1 reference

12 November 2017

Kentaro Yoshioka

3

1 reference

12 November 2017

Hisataka Moriwaki

4

1 reference

12 November 2017

Takashi Okanoue

5

1 reference

12 November 2017

Shotaro Sakisaka

6

1 reference

12 November 2017

Tetsuo Takehara

7

1 reference

12 November 2017

Makoto Oketani

8

1 reference

12 November 2017

Joji Toyota

9

1 reference

12 November 2017

Yoichi Hiasa

11

1 reference

12 November 2017

Akihiro Matsumoto

12

1 reference

12 November 2017

Hideyuki Nomura

13

1 reference

12 November 2017

Masataka Seike

14

1 reference

12 November 2017

Yoshiyuki Ueno

15

1 reference

12 November 2017

Hiroshi Yotsuyanagi

16

1 reference

12 November 2017

publication date

19 January 2011

1 reference

Journal of Gastroenterology

12 November 2017

published in

1 reference

12 November 2017

volume

46

1 reference

12 November 2017

issue

4

1 reference

12 November 2017

page(s)

545-555

1 reference

Hepatitis C: the clinical spectrum of disease

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Hepatitis C: the clinical spectrum of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Viral Determinants of Resistance to Treatment in Patients with Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Expert opinion on the treatment of patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Predictive model of biliocystic communication in liver hydatid cysts using classification and regression tree analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Predicting early mortality after acute variceal hemorrhage based on classification and regression tree analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0358-6

Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection

21 January 2018

1 reference

PubMed

12 December 2020

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

Classification of chronic hepatitis: diagnosis, grading and staging

1 reference

PubMed

12 December 2020

10.1007/S00535-010-0358-6

Identifiers

DOI

1 reference

12 November 2017

1 reference